Why Australia is a prime destination for drug discovery projects
23 December, 2020There are several compelling reasons why companies should consider Australia as the best location for their next chemistry and drug development partnership.
New polio vaccine is more genetically stable
17 December, 2020Scientists have developed the first poliovirus vaccine against a mutated form of the disease that is causing disease outbreaks across Africa and Asia.
New insulin molecule can self-regulate blood sugar
15 December, 2020A new insulin molecule should make blood sugar regulation both easier and safer for those with type 1 diabetes, ensuring they receive just the right amount of insulin.
Brain implants could restore rudimentary vision in the blind
14 December, 2020Restoration of vision in blind people is on the verge of becoming reality, with high-resolution implants making it possible to recognise artificially induced shapes and percepts.
UQ COVID-19 vaccine dropped after false positive HIV results
11 December, 2020 by Lauren DavisUQ and CSL's COVID-19 vaccine candidate will not proceed to Phase 2/3 clinical trials following reports of false positive HIV results in study volunteers.
Oxford first to publish peer-reviewed COVID-19 vaccine results
09 December, 2020Interim results of the University of Oxford's COVID-19 vaccine Phase 3 trials find that the vaccine protects against symptomatic disease in 70% of cases on average.
Moderna vaccine reports 100% efficacy against severe COVID-19
02 December, 2020Primary efficacy analysis of the Phase 3 study of Moderna's COVID-19 vaccine candidate, mRNA-1273, has confirmed a vaccine efficacy of 94.1%.
Mini kidneys bioprinted in the lab
01 December, 2020The bioprinting method is faster and more reliable than previous methods, with the ability to create about 200 mini kidneys in 10 minutes without compromising quality.
Oxford COVID-19 vaccine meets primary efficacy endpoint
25 November, 2020Interim Phase 3 trial data shows that the vaccine candidate AZD1222 is effective at preventing COVID-19 and offers a high level of protection.
Pfizer/BioNTech COVID-19 vaccine meets primary endpoints
20 November, 2020Pfizer and BioNTech have completed the final efficacy analysis in the ongoing Phase 3 study of their mRNA-based COVID-19 vaccine candidate, BNT162b2.
High efficacy, long shelf life for Moderna's COVID-19 vaccine
18 November, 2020Interim analysis of Moderna's Phase 3 study of mRNA-1273 finds that the COVID-19 vaccine candidate has an efficacy of 94.5% and remains stable at -20°C for up to six months.
Simple medical device helps to reverse alcohol intoxication
16 November, 2020ClearMate allows a patient to hyperventilate off the alcohol in their system while returning precisely the amount of carbon dioxide to the body to keep it at normal levels in the blood.
Russia claims 92% efficacy for COVID-19 vaccine
13 November, 2020 by Lauren DavisHot on the heels of Pfizer and BioNTech's SARS-CoV-2 vaccine candidate, Russia's Sputnik V has demonstrated high efficacy of 92%.
Pfizer and BioNTech's COVID-19 vaccine shows 90% efficacy
10 November, 2020Pfizer and BioNTech say their SARS-CoV-2 vaccine candidate has proved more than 90% effective in preventing COVID-19 in participants without prior evidence of infection.
Aus Govt secures two more COVID-19 vaccine agreements
06 November, 2020The Australian Government has secured 50 million more doses of COVID-19 vaccines, as a result of new agreements with Novavax and Pfizer/BioNTech.
